Document is current
Any future updates will be listed below
-
Authors
Perez, Kimberly J. https://orcid.org/0000-0002-5745-2994
Dias Costa, Andressa https://orcid.org/0000-0003-1046-4899
Jordan, Alexander
Karasic, Thomas B. https://orcid.org/0000-0001-9157-5392
Elganainy, Dalia https://orcid.org/0000-0003-4427-986X
Kim, Suryun
Yuan, Chen
Gui, Dan Y.
Tan, Runzi https://orcid.org/0009-0002-3680-7642
Hong, Sung Chul
Wang, Xi https://orcid.org/0000-0003-2497-9439
Cristea, Simona https://orcid.org/0009-0003-1276-186X
Coleman, Emma https://orcid.org/0009-0000-6010-9970
Truitt, Morgan
Oh, Tae Gyu
Zheng, Hui https://orcid.org/0000-0001-6725-1910
Furniss, C. Sloane
Brais, Lauren
Bird, Alexandra
Remland, Josh https://orcid.org/0009-0004-5655-0762
Gocheva, Vasilena
Thalappillil, Jennifer S. https://orcid.org/0000-0002-4860-3033
Anderson, Mark
Cleary, James M.
Enzinger, Andrea
Giannakis, Marios https://orcid.org/0000-0001-9012-6982
Ng, Kimmie https://orcid.org/0000-0003-0631-1494
Rubinson, Douglas A. https://orcid.org/0000-0002-5337-5231
Schlechter, Benjamin https://orcid.org/0000-0002-1529-3278
Surana, Rishi
Singh, Harshabad https://orcid.org/0000-0001-6295-2013
Abrams, Thomas
Teitelbaum, Ursina
Izgur, Natallia
Allen, Eliezer https://orcid.org/0000-0002-0201-4444
Winter, Peter S.
Raghavan, Srivatsan https://orcid.org/0000-0002-5374-9918
Yeh, Jen Jen
Von Hoff, Daniel https://orcid.org/0000-0003-4723-7681
Liddle, Christopher
Downes, Michael
Evans, Ronald M. https://orcid.org/0000-0002-9986-5965
O’Dwyer, Peter https://orcid.org/0000-0002-9302-4073
Aguirre, Andrew https://orcid.org/0000-0002-0701-6203
Nowak, Jonathan A. https://orcid.org/0000-0002-0943-7407
Wolpin, Brian M. https://orcid.org/0000-0002-0455-1032
-
Funding
Funding for this research was provided by:
American Association for Cancer Research
EIF | Stand Up To Cancer
Lustgarten Foundation
- License Information
-
More Information
Article History
Received: 1 January 2025
Accepted: 8 April 2026
First Online: 25 May 2026
Competing interests
: The authors declare the following competing interests: K.J.P.: The authors held a one-time advisory role for Ipsen, Exelixis and Novartis. J.M.C.: The author receives research funding to his institution from Amgen, Merus, Servier and Bristol Myers Squibb. He receives research support from Merck, AstraZeneca, Esperas Pharma, Bayer, Tesaro, Arcus Biosciences and Pyxis; he has also received honoraria for being on the advisory boards of Incyte and Blueprint Medicines and for serving on the data safety monitoring committee for AstraZeneca. He has given educational talks sponsored by Bayer, Bristol Myers Squibb, Lilly, Merck, AstraZeneca and Genentech. A.E.: The author receives research funding from Medtronic, Inc. Spouse has been a consultant for and has received honoraria from ALX oncology, Arcus Bioscience, Astellas, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Chimeric Therapeutics, Celgene, Coherus, Daiichi-Sankyo, Five Prime, Ideaya, Istari, Legend, Lily, Loxo, Merck, Novartis, Ono, Servier, Taiho, Takeda, Turning Point Therapeutics, Xencor and Zymeworks. D.A.R.: The author receives research funding Instylla, Boston Scientific, Axial Therapeutics, Taiho, Sirtex. H.S.: The author receives research funding from AstraZeneca, has consulted for Dewpoint Therapeutics, Inc. and Merck Sharp & Dohme, LLC. Travel and accommodation from Dava Oncology. Honoraria from UpToDate. T.A.: The author receives research funding to his institution from Lilly, Sanofi; receives consulting fees from Eisai and AstraZeneca; stock ownership in Merck. P.S.W.: Receives research support from Microsoft and reports compensation for consulting from The Engine Ventures unrelated to this work. S.R.: Research support from Microsoft, equity in Amgen. T.B.K.: Research support to institution from AstraZeneca, Eli Lilly, Tempest Therapeutics, Xencor, Genentech, Totus Medicines, Boehringer Ingelheim, Replimune, BioNTech, PMV Pharma and Frontier Medicines. Consulting/advisory boards for Pfizer, Merus, Incyte, Nucorion Pharmaceuticals and Synnovation Therapeutics. P.O.D.: Research Support: Pfizer, BMS, AZ, GSK, Five Prime, Merck, Syndax, BBI, Novartis, Celgene, Incyte, Lilly/Imclone, array, h3biomedicine, Taiho, Minneamrata, pharmacyclics/abbvie, Mirati. J.A.N.: The author receives research funding from Natera and serves as a consultant for Leica Biosystems. B.M.W.: Research funding to institution: Amgen, AstraZeneca, BMS/Celgene, BreakThrough Cancer, Eli Lilly, Harbinger Health, Lustgarten Foundation, NIH/NCI, Novartis, Pancreatic Cancer Action Network, Revolution Medicines, Servier/Agios, Stand Up to Cancer. Advisory boards/consulting: Agenus, BMS/Mirati, EcoR1 Capital, GRAIL, Harbinger Health, Ipsen, Lustgarten Foundation, Revolution Medicines, Tango Therapeutics, Third Rock Ventures. The other authors declare no competing interests.
